Clinical experience with the use of daptomycin in a tertiary care teaching hospital in Barcelona, Spain

Nancy Sandoval, Santiago Grau, Luisa Sorlí, Milagro Montero, Erika Esteve, Juan Pablo Horcajada

Research output: Contribution to journalReview articleResearchpeer-review

5 Citations (Scopus)

Abstract

© 2015 Future Medicine Ltd. Aim: We reviewed the clinical use of daptomycin in daily practice. Materials & methods: Efficacy and safety were assessed in 175 consecutive patients given daptomycin for at least 72 h. Results: Daptomycin was given as rescue treatment in 50.9% of cases. Bloodstream infection (34.8%) and skin/soft-tissue infection (19.4%) were the most frequent. In 62.3% of patients, the dose of ≤ 6 mg/kg/day was administered. Staphylococcus spp. were isolated in 52.6% of cases (MRSA in 9.5%, CoNS in 34.3%) and Enterococcus spp. in 8.7%. Clinical success was 75% and microbiological eradication 48.6%. Two patients discontinued daptomycin due to hemolytic anemia of unlikely and possible relationship with daptomycin, respectively. Conclusion: Daptomycin was effective and well tolerated in patients with severe Gram-positive infections.
Original languageEnglish
Pages (from-to)1145-1154
JournalFuture Microbiology
Volume10
Issue number7
DOIs
Publication statusPublished - 1 Jan 2015

Keywords

  • bacteremia
  • clinical outcome
  • daptomycin
  • Gram-positive infections
  • retrospective study

Fingerprint Dive into the research topics of 'Clinical experience with the use of daptomycin in a tertiary care teaching hospital in Barcelona, Spain'. Together they form a unique fingerprint.

Cite this